Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal.
Curr Pharm Des. 2013;19(2):290-9. doi: 10.2174/138161213804070276.
The most common treatments for infectious diseases target the invading pathogen. The efficacy of such an approach may, however, be countered by the possibility of the development of resistance to a pharmacophore, through mutation(s) in pathogen molecules required for activity. Given the fact that pathogens exploit host factors in order to grow in an otherwise hostile environment, one possible way to circumvent the emergence of resistance is to develop drugs that target non-essential host factors hijacked by the pathogen, rather than the pathogen's own molecules. Such solutions are already being developed for various viral and bacterial pathogens, but much less has been achieved with infections caused by protozoan parasites, as is the case of Plasmodium. Here, we highlight recent progress in host target-based anti-viral and anti-bacterial approaches and discuss possible host targets that may be used for anti-malarial interventions. Host molecules that play a role during either the liver or the blood stage of Plasmodium infection are outlined and their potential merits as anti-malarial targets are discussed.
针对传染病的最常见治疗方法是针对入侵病原体。然而，通过病原体分子的突变（s），可能会对药效团产生抗药性，从而影响这种方法的疗效，这些分子对于活性是必需的。鉴于病原体利用宿主因子在恶劣环境中生长的事实，规避抗药性出现的一种可能方法是开发靶向被病原体劫持的非必需宿主因子的药物，而不是针对病原体自身的分子。已经针对各种病毒和细菌病原体开发了此类解决方案，但对于由原生动物寄生虫引起的感染（如疟原虫），取得的成果要少得多。在这里，我们重点介绍基于宿主靶标的抗病毒和抗细菌方法的最新进展，并讨论可能用于抗疟干预的宿主靶标。概述了在疟原虫感染的肝脏或血液阶段起作用的宿主分子，并讨论了它们作为抗疟靶标的潜在优点。
